Occupational asthma is asthma that is induced solely by asthma-causing substances in the work environment. Occupational asthma accounts for about 2% to 7% of the total number of people with asthma worldwide, while in industrially developed countries (e.g., the United States) occupational asthma accounts for about 15% of the total number of people with asthma. A review of the literature on occupational asthma by Dr. Tarlo of the University of Toronto Faculty of Medicine and Dr. Lemiere of the University of Montreal was published in the New England Journal of Medicine on February 13 of this year. The researchers concluded that most occupational asthma can be prevented. In addition, increased awareness of occupational asthma may strengthen our understanding of other subtypes of asthma. To reduce the risk of long-term occupational asthma injury, health care providers should fully consider the possibility of occupational asthma when confirming the diagnosis of adult patients with asthma symptoms. The incidence of occupational asthma is related to the nature of the asthma-causing agent in the work environment; for example, the incidence of occupational asthma is about 5% to 10% in workers with long-term exposure to the asthma-causing agent isocyanate, and up to 50% or more in workers engaged in the decontaminant industry with long-term exposure to protein hydrolases. Specific bronchial excitation test is the most diagnostic method to diagnose occupational asthma and screen for occupational asthma-causing substances. However, so far, not many occupational disease control institutions in China can carry out this test. With the establishment and development of many small rural enterprises in China, the number of occupational asthma patients in China is rapidly increasing. However, there is a lack of relevant epidemiological survey data, a lack of sound prevention and control institutions and management teams, and no laws and regulations to prevent and control occupational asthma in line with our national conditions. Many occupational asthma patients in private enterprises are not only unable to receive the treatment that occupational disease patients should enjoy as stipulated by the state, but often even the standardized treatment that asthma patients should receive is not guaranteed. Patients with occupational asthma without standardized treatment often experience airway remodeling, irreversible airway obstruction, progression to chronic obstructive pulmonary disease or pulmonary heart disease (pulmonary heart disease), and eventually respiratory failure and heart failure, in addition to recurrent episodes of wheezing that make it difficult to perform normal work and life. To date, the literature has reported upwards of 250 asthma-causing factors that may be associated with occupational asthma, but only five categories of occupational asthma are currently recognized in China, including isocyanates, phthalic anhydrides, amines, platinum complex salts, and sisal. This means that many occupational asthma cannot be legally recognized and diagnosed at present. Timely diagnosis of occupational asthma, timely removal from the original disease-causing work environment, and long-term standardized treatment with inhaled glucocorticoids (ICS) and other medications are the 3 keys to preventing and treating occupational asthma. Occupational asthma requires the joint care and assistance of asthma specialists and occupational physicians. However, many occupational physicians in China are not familiar with modern asthma prevention and treatment techniques, while specialists who have mastered the techniques of diagnosing and treating asthma are not qualified to diagnose and manage occupational asthma. Clinicians who encounter very typical cases of occupational asthma in outpatient clinics or wards are unable to make a diagnosis of occupational asthma and have to send these patients to the local occupational disease control center. Many of these patients did not receive timely and effective diagnosis and treatment. This is because occupational asthma has not yet received sufficient attention from occupational physicians in China compared to traditional occupational diseases such as pneumoconiosis. In summary, if the prevention and treatment of bronchial asthma and occupational diseases in China are lagging behind those in developed countries in Europe and the United States, the gap in the prevention and treatment of occupational asthma is even greater and therefore needs more attention!